002393.SZ
力生制药
SZSE · Healthcare · C 制造业 · CN
CNY 13.82
−4.16%Year over year
Reported trailing growth
- Revenue
- +1.0%
- EBITDA
- —
- EBIT
- +107.1%
- EPS
- +128.9%
- Free cash flow
- +621.1%
- Operating cash flow
- +3541.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.7%
- EBITDA
- +43.8%
- EBIT
- +58.4%
- Net income
- +64.4%
- EPS
- +47.0%
- Free cash flow
- -10.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026